Benzonaphthyridine Adjuvants for Subunit Vaccine Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Subunit vaccines, which are safer and cheaper to produce than traditional live and killed vaccines, face challenges due to limited immunogenicity, necessitating the use of adjuvants to enhance immune response, while traditional live vaccines often do not require adjuvants and killed vaccines have varying immunogenicity.
Innovation Solution
The development of immunogenic compositions comprising a first antigen, biodegradable polymeric particles, and a benzonaphthyridine compound, which enhances the immune response by combining these components to improve vaccine efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If subunit vaccines are used, then safety and production cost are improved, but immunogenicity deteriorates
Solution Approach 1:
The patent introduces adjuvants as intermediary substances that mediate between the subunit vaccine antigen and the immune system. These adjuvants enhance the immune response to the isolated polypeptide antigens, effectively bridging the gap between the safe but weakly immunogenic subunit vaccines and the desired strong immune protection
Solution Approach 2:
The patent creates composite vaccine formulations by combining subunit vaccine antigens with adjuvant materials. This composite approach integrates the safety benefits of recombinant DNA technology with the immunostimulatory capabilities of adjuvants, achieving both safety and enhanced immunogenicity in a single formulation
2Object-affected harmful factors
If killed vaccines are used, then immunogenicity is improved, but safety deteriorates
Solution Approach 1:
The patent extracts only the essential antigenic components (isolated polypeptides) from whole killed vaccines, removing the need for adjuvants while retaining immunogenicity where possible, or pairing them with safer adjuvant systems that do not require killed organisms
Solution Approach 2:
The patent uses recombinant DNA technology to create synthetic copies of viral or bacterial proteins in safe host systems (e.g., bacteria, yeast, mammalian cells), producing identical antigenic structures without the risks associated with killed vaccines
3Object-affected harmful factors
If adjuvants are added to subunit vaccines, then immune response is improved, but formulation complexity increases
Solution Approach 1:
The patent optimizes adjuvant parameters such as concentration, particle size, and composition ratios to achieve enhanced immune responses with simplified formulations. By carefully controlling these parameters, the patent reduces the number of components needed while maintaining or improving efficacy
Data Source
Figure 1~2
Figure 3~5
Figure 6~7
AI summary
The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) polymeric particles and (c) a benzonaphthyridine compound, which compositions elicits an immune response when administered to a vertebrate subject. The invention also provides, inter alia, methods of producing immunogenic compositions and methods for using immunogenic compositions (e.g., for treatment), among other benefits.